171 results about "Pulmonary Injury" patented technology

A medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist topically exhibits a prolonged bronchodilating and antiinflammatory effects. Namely, the medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist is useful as a safe preventive and / or a remedy for respiratory diseases (for example, asthma, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, cystic fibrosis, pulmonary hypertension or the like) without causing any systemic effect such as lowering blood pressure. Thus, a safe and useful remedy for respiratory diseases is provided.

The invention relates to the technical field of medical science, in particular to new application of a ferroptosis inhibitor. The ferroptosis inhibitor is prepared from Liproxstatin-1, Ferrostatin-1,rosiglitazone, pioglitazone, troglitazone and Zileuton. The new application refers to that the inhibitor is applied to treating radiation-induced pulmonary injury diseases. The application has the advantages that (1) radioactive rays trigger radiation-induced pulmonary injury by mediating pulmonary alveoli epithelial cells to have ferroptosis, the ferroptosis specificity inhibitor can be used to prevent and treat radiation-induced pulmonary injury, and has the important meaning on development of new drug for preventing and treating radiation-induced pulmonary injury; and (2) it is found that radioactive rays can cause cell death through the mode of ferroptosis, and application of the ferroptosis inhibitor also has the significant theoretical meaning on guiding research for guiding radioactive rays to treat cancer mechanism.

The invention discloses mesenchymal stem cells genetically modified with an angiopoietin 1 gene and a construction method and application thereof. The mesenchymal stem cells carry the angiopoietin 1 gene. Tests prove that the mesenchymal stem cells genetically modified with an angiopoietin 1 gene can overexpress angiopoietin 1; after venous re-transfusion, the angiopoietin 1 is overexpressed in the pulmonary tissue, so that pulmonary pathological injuries, pulmonary inflammatory response and pulmonary edema are obviously relieved, and an obvious and long-lasting effect is achieved; and the mesenchymal stem cells genetically modified with angiopoietin 1 gene and the construction method thereof are expected to provide a suitable microenvironment for repair of the pulmonary injuries, and have a wide application prospect.

The invention provides a method for establishing a zebra fish bladder injury inflammation model and a method for evaluating efficacies of a lung injury therapeutic agent and inductive agent by use of the zebra fish bladder injury inflammation model. The zebra fish bladder injury inflammation model provide by the invention has the advantages of simplicity and convenience, rapidness, economical efficiency, high efficiency, high flux and the like, can accurately reflect the real in-vivo condition of the lung injury therapeutic agent or inductive agent, and can realize the in-vivo high-flux evaluation on the efficacy of a medicament in treating acute lung injury inflammation, and the method for evaluating the efficacy of the medicament by use of the zebra fish bladder injury inflammation model has the advantages of reliability, rapidness, high efficiency, low cost, high cost performance and the like, and has great significance.

The invention discloses application of kaempferol in preparation of medicines for preventing and treating radiation-induced pulmonary injury. The experiment proves that kaempferol can obviously improve inflammatory exudation of lung tissues suffering from the mouse radiation-induced pulmonary injury and has an excellent positive effect on the radiation-induced pulmonary injury. The invention provides a novel drug for radiation-induced pulmonary injury diseases. A novel thought is provided for research and development of medicines for treating the radiation-induced pulmonary injury, and the application path of kaempferol in the field of medicines is widened.

During lung injury, p53 expression increases, inducing plasminogen activator inhibitor-1 (PAI-1) while inhibiting expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), resulting in apoptosis of lung epithelial cells (LECs). In the bleomycin lung injury model, p53 and PAI-1 are induced while uPA and uPAR are inhibited. A 20 residue peptide DGIWKASFTTFTVTKYWFYR termed PP-1 (the Cav-1 scaffolding domain) or peptide NYHYLESSMTALYTLGH, termed PP-2, protected LECs from bleomycin-induced apoptosis in vitro and in vivo and prevented subsequent pulmonary fibrosis by attenuating lung epitheilial damage. Pharmaceutical compositions, peptide multimers and deliverable polypeptides comprising the above peptides are dislcosed. The peptides and functional variants, peptide multimers, cell-targeted polyepeptides and pharmaceutical compositions are used in methods for inhibiting apoptosis of injured or damaged lung epithelial cells and for treating acute lung injury and consequent pulmonary fibrosis.

The invention discloses application of oridonin powder aerosol in treatment of acute lung injury. The oridonin powder aerosol is prepared by an oridonin nano-drug delivery system, wherein the dosage form of the nano-drug delivery system is selected from lipidosome, nanoparticles, nanosuspension, nanoemulsion and micro-emulsion. The medicines in the oridonin powder aerosol are stable, easily enter the deep parts of lung tissues, are positioned in a targeted mode and are convenient to carry and use, and the treatment of acute lung injury is promoted. The oridonin powder aerosol is used for treating the acute lung injury caused by infection, shock, smoking, trauma, toxin poisoning, inhalation of irritant gases, radiation, high oxygen and low oxygen, wherein the inhaled irritant gases comprise phosgene, diphosgene, triphosgene, chlorine, nitric oxides, formaldehyde, dimethyl sulfate, hydrogen chloride, hydrogen bromide, hydrogen fluoride, ammonia, ozone and sulfur dioxide.

The invention discloses an application of a dry curcumin nano-powder inhalant in treatment of acute lung injury. The dry curcumin nano-powder inhalant is prepared from a curcumin nanometer administration system. The dosage form of the curcumin nanometer administration system is selected from a liposome, a nano-particle, a nano-emulsion and a micro-emulsion. The curcumin nanometer administration system with or without auxiliary materials is dried to form a solid powder, and the solid powder is mixed with a carrier to obtain the dry curcumin nano-powder inhalant. The dry curcumin nano-powder inhalant has the advantages of stable drugs, easy entrance of the deep portion of lung tissues, targeted positioning, carrying and use convenience, and benefiting for the treatment of the acute lung injury. The dry curcumin nano-powder inhalant is used for treating acute lung injury caused by infection, shock, smoking, wounds, poisoning, irritating gas inhalation, radiation, high oxygen and low oxygen. Irritating gases comprise phosgene, diphosgene, triphosgene, chlorine, nitrogen oxide, formaldehyde, dimethyl sulfate, hydrogen chloride, hydrogen bromide, hydrogen fluoride, ammonia, ozone and sulfur dioxide.

The invention relates to the technical field of medical diagnosis mathematical modeling, and particularly relates to a gas explosion lung injury diagnosis system, a serum marker screening method and alung injury action mechanism research method. According to the invention, a serum metabonomics analysis model is constructed based on LC-MS to obtain a PLS-DA model; and nine specific biomarkers withthe effect of causing gas explosion lung injury are obtained by screening through a metabonomics research method, so that the diagnosis and treatment efficiency of coal mine full-gas explosion injurycrowds is effectively improved, important clinical value and social significance are achieved, and the popularization and application are facilitated. The identification and high-throughput analysisof the action mechanism of the gas explosion lung injury are achieved through a standard substance of BioNovoGene company and the HMDB, massbank, Metlin and KEGG databases, the gas explosion lung injury action mechanism is comprehensively analyzed and evaluated on the overall level, and guidance and predictive research are provided for clarification of metabonomics and the action mechanism of thecoal mine gas explosion lung injury.

The invention relates to a traditional Chinese medicine composition for treating radiation-induced pulmonary injury. The traditional Chinese medicine composition is characterized by being prepared from the following bulk drugs by weight: 8-10g of codonopsis pilosula, 6-8g of radix astragali, 4-6g of Chinese angelica, 6-8g of radix scutellariae, 6-8g of cordate houttuynia, 8-10g of figwort root, 6-9g of dried rehmannia root, 4-6g of salvia miltiorrhiza, 6-8g of radix paeoniae alba, 4-6g of ligusticum wallichii, 4-6g of bitter almond, 6-8g of dried orange peel, 4-6g of platycodon grandiflorum, 4-6g of earthworm, 6-8g of frankincense, 6-8g of myrrh and 4-6g of liquorice. The traditional Chinese medicine composition has the beneficial effects of strengthening the body resistance and eliminating pathogenic factors, nourishing yin and promoting the secretion of saliva or body fluid, moistening lung for arresting cough, and invigorating blood and removing stasis, is rapid in taking effect and high in curative effect, and has no toxic or side effect. Diagnosis and treatment based on the overall analysis of the illnesses and the conditions of patients can be performed in clinic.

The invention discloses application of exosome in preparing a medicine for treating interstitial lung injury and / or pulmonary fibrosis, and belongs to the technical field of medicines. According to the present invention, it is found for the first time that the exosome can be used for preparing the medicine for treating the interstitial lung injury and / or pulmonary fibrosis, the new application field of the exosome is expanded, the new medicine for treating the interstitial lung injury and pulmonary fibrosis is also expanded, and wide application prospects are achieved.

The present invention relates to a method of using trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol for treating acute pancreatitis in a subject in needs thereof. More particularly, the present invention relates to a method of using dihydro-resveratrol, its derivatives and / or chemical variants as a remedial agent. The present invention particularly relates to the amelioration of tissue injury for the management of acute pancreatitis associated pulmonary injury of a subject.

A medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist topically exhibits a prolonged bronchodilating and antiinflammatory effects. Namely, the medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist is useful as a safe preventive and / or a remedy for respiratory diseases (for example, asthma, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, cystic fibrosis, pulmonary hypertension or the like) without causing any systemic effect such as lowering blood pressure. Thus, a safe and useful remedy for respiratory diseases is provided.

The invention relates to the field of new application of drugs, specifically to application of glucosamine in preparation of a drug for preventing and treating ionizing radiation induced pulmonary injury. The structure formula of glucosamine is shown in the description. The glucosamine is used as the drug for preventing and treating ionizing radiation induced pulmonary injury, and is small in toxic and side effects, and obvious in treatment effect; the glucosamine is applied based on the concentration of 100mg / kg / d in first three days of radiation; the pulmonary tissue can be obviously protected and is inhibited from epithelial-mesenchymal transition, which is the unique feature of the glucosamine in preventing and treating of ionizing radiation induced pulmonary injury; the glucosamine has a good application prospect in the Chinese medical field.

The invention discloses an external ointment for treating injuries from falls and a preparation method thereof, and belongs to the field of science of Chinese materia medica. The external ointment disclosed by the invention comprises the following raw materials: stachys sieboldii, erianthus arundinaceus, cape bracketplant herb with root, sedum aizoon, tomentulose corydalis dried herb, edgeworthia chrysantha, henry biondia herb with root, vaccinium bracteatum, piper hancei maxim, begonia evansiania, elaeocarpus hainanensis, comely indigo, semen cuscutae, effuse baliospermum root and leaf, lacerate wood fern rhizome or leaf and plexippus. The external ointment disclosed by the invention has the effects of expelling wind and relieving pain, promoting blood circulation to remove blood stasis, stopping bleeding and promoting granulation, and clearing away heat and drying dampness, can be widely applied to treatment of various injuries from falls such as falls, crush injuries, contused wounds, sprains and the like, and has an accurate curative effect on soft tissue injuries such as joint sprains, pulled muscle, blood stasis and swelling and the like. In addition, the external ointment also can be applicable to indisposition caused by various severe and lingering pulmonary injuries and sprains, and is significant in curative effect, quick to take effect, free of toxic and side effects, low in cost and worthy of wide popularization and application in large hospitals.

The invention discloses a method for establishing an acute lung injury animal model, and relates to the technical field of bioengineering. The method for establishing the acute lung injury animal model comprises the following steps: anesthetizing and fixing an experimental animal; inducing acute lung injury of the experimental animal by combining hydrochloric acid with mechanical ventilation; andevaluating the degree of acute lung injury. According to the method, acute pathological injury of the lung of the experimental animal is induced by combining hydrochloric acid with mechanical ventilation, the animal model of acute lung injury can be constructed, and the animal model shows typical characteristics of acute lung injury, such as dyspnea, lung tissue edema and lung tissue fibrosis. Themodel can be used for basic research in the related field of acute lung injury, and lays an experimental animal foundation for exploring the pathogenesis of acute lung injury.

The invention discloses a respirator device capable of performing ventilation monitoring. The respirator device comprises an air bag, an air guide pipe, a one-way valve, an air storage bag, a safety pressure valve, an exhalation valve, a connecting valve, an airflow sensor, a displayer, a pressurizing mask and an air inlet; one end of the air guide pipe is fixedly connected with one end of the airbag; the one-way valve is sleeved on the air guide pipe; the air inlet is embedded in the air bag; the respirator device has the following beneficial effects, the respirator device is reasonable in design and novel structure, the use method is simple, the operation is convenient, when the simple respirator is used, the display is matched with the airflow sensor, the tidal volume and the ventilation frequency can be displayed in real time, the lung injury caused by invalid use of the simple respirator or wrong use is prevented, the ventilation parameters of the simple respirator can be visually displayed, the reliable data guidance is provided for operators, even inexperienced operators, and the situation that invalid operation or wrong operation aggravates the illness state of a patient is avoided.

The invention discloses a new usage of safflower yellow prepared through the extraction from traditional Chinese medicine safflowers during the preparation of a medicine for treating and / or preventing lung injury, in particular the invention discloses a new usage in the preparation of a medicine for treating and / or preventing acute lung injury cased by lung ischemia reperfusion injury, pulmonary embolism or inflammatory reaction which is the result of the action of inflammatory agent onto the lung. The invention also discloses a medicine made from the safflower yellow and a preparation of the medicine thereof.

The invention discloses a novel application of N-(2-phenylethyl)-5-phenyl-pyridine-2-formamide. The novel application of the medicine provided by the invention is the application of N-(2-phenylethyl)-5-phenyl-pyridine-2-formamide in preparing the medicine for treating / preventing lung injury of mammals. Research finds that N-(2-phenylethyl)-5-phenyl-pyridine-2-formamide has a certain prevention and treatment effect on rat ALI caused by LPS and has an effect of inhibiting inflammatory reaction on RAW264.7 macrophages stimulated by LPS, and the action mechanism can regulate expression of IL-6 and IL-1beta, and is also related to inhibition of hypoxia inducible factor HIF-1alpha by N-(2-phenylethyl)-5-phenyl-pyridine-2-formamide and glycolysis and activation of an acid-sensitive ion channel ASIC1a; researches show that N-(2-phenylethyl)-5-phenyl-pyridine-2-formyl can relieve lung tissue injury caused by LPS, improve respiratory metabolism functions of rats with lung injury, improve pulmonary edema of the rats with lung injury, relieve inflammatory response and inhibit inflammatory diseases related to ASIC1a.

The invention discloses Chinese medicine combination for preventing and curing lung injury and pulmonary fibrosis and a preparation method thereof. The Chinese medicine combination comprises the following components in percentage by weight: 28.6 percent of balloonflower root, 28.6 percent of Zhejiang fritillary bulb, 21.4 percent of flos lonicerae, and 21.4 percent of moutan bark; the method for preparing oral liquid comprises the following steps: weighing all the components in percentage by weight, mixing and smashing the components through a 100-mesh sieve, adding mixed powder into a container, adding 500 ml of water into the container, boiling the water and then keeping boiling for 45 minutes, precipitating, filtering, fetching filtrate to be conducted to vacuum concentration to 100 ml, filling concentrated solution into bottles, ensuring that each bottle is 100 milliliters, and then performing sterilizing sealing; the method for preparing capsules comprises the following steps: weighing all the components in percentage by weight, mixing and smashing the components through a 100-mesh sieve, boiling 3 / 4 of the medicine for 45 mutinies, precipitating, filtering, fetching filtrate to be conducted to vacuum concentration to 100 ml, smashing 1 / 4 of the medicine again through a 200-mesh sieve to be uniformly mixed with the liquid medicine, performing vacuum drying or low-temperature drying, sterilizing, encapsulating, and ensuring that each capsule is 0.25 g. The Chinese medicine combination ensures that lung is prevented from chemotherapeutics injury and radiation injury, is resistant to pulmonary fibrosis, and does not have toxic side effect and untoward effect.

The invention discloses an application of 1,8-dihydroxy-3-methylanthraquinone in preparing a medicine for treating acute lung injury. The 1,8-dihydroxy-3-methylanthraquinone provided by the inventionshows a good therapeutic effect on a lipopolysaccharide-induced acute lung injury mouse model and can effectively regulate NF-kappa B and NLRP3 signaling pathways, experiments confirm the 1,8-dihydroxy-3-methylanthraquinone has a significant anti-inflammatory effect on the acute lung injury and can effectively promote the lung injury repair in the middle and late stages of the acute lung injury, so that the 1,8-dihydroxy-3-methylanthraquinone can be used for preparing the medicine for treating the acute lung injury. A novel approach is provided for the treatment of the acute lung injury.

The invention belongs to the technical field of traditional Chinese medicine fermentation, and provides astragalus membranaceus fermentation liquor as well as a preparation method and application thereof. The preparation process comprises the following steps of soaking astragalus membranaceus slices in water, decocting, and filtering to obtain medicine residues and first medicine liquid, adding water into the medicine residues, and decocting to obtain second medicine liquid, combining the first medicine liquid and the second medicine liquid, and concentrating to obtain an astragalus membranaceus water extract, mixing lactobacillus plantarum LZU-S-ZCJ with LZU-J-TSL6, and inoculating the mixture into the astragalus membranaceus water extract for fermentation, so as to obtain the astragalus membranaceus fermentation liquor. The astragalus membranaceus fermentation liquor obtained by the method disclosed by the invention can relieve the edema degree of mouse lungs, relieve the inflammatory cell infiltration state caused by lipopolysaccharide (LPS), reduce the accumulation of protein liquid in the mouse lungs, reduce the concentration of inflammatory factors in BALF of mice with acute lung injury, regulate the frontal intestinal flora of the mice with acute lung injury and the like, can be used for treating acute lung injury, and has a good effect of relieving mouse acute lung injury.

The invention discloses application of quercetin in a drug for preventing and treating acute radiation pneumonitis and a preparation prepared from the quercetin. The quercetin can be used for remarkably improving inflammatory exudation of mice radiation-induced pulmonary injury lung tissue, has a certain preventing and treating effect for the radiation-induced pulmonary injury, so that a novel material drug is provided for treating the acute radiation pneumonitis.

The invention provides a method for establishment of an acute lung injury model of tree shrews and application of the model. After the tree shrews are narcotized, 180-200 mg / kg of a lipopolysaccharidesolution is intratracheally administrated, and when the lung injury area of the tree shrews reaches a half or more, the acute lung injury animal model of the tree shrews is established. Through the establishment method, lung injury of the tree shrews can reach a half or more after 70 hours; in 96 to 120 hours, the tree shrews clinically show the symptoms of wasting, breathing difficulties and thelike, the lung injury area of the tree shrews is 70% or more, and the blood oxygen index can reach 200 mmHg or below. The modeling method is efficient and high in success rate, and the cost can be effectively saved; the model cycle is 70 hours or more, and the research cycle space for acute lung injury is significantly widened; and the established tree shrew animal model is incapable of self-healing and reversible recovery, the clinical symptoms are more similar to human diseases, and good prospects of industrialization are achieved.

The invention relates to a preparation method of a radioactivity lung injury rabbit-step model. The preparation method of the radioactivity lung injury rabbit-step model is characterized in that anesthesia is carried out through intramuscular injection, and then a single full lung field gray high-energy x ray is used for radiating after fixing is achieved. In addition, a control group which is healthy and not radiated is established, observation research is carried out in different time points after radiation, and finally a radioactivity lung injury rabbit-step model is successfully established after being verified by results of blood serum, pathology, an electron microscope, high-resolution computed tomography (CT), CT perfusion weighted imaging and the like. An animal model established by the preparation method can well simulate happening and developing regular patterns and characteristics of human radioactivity lung injury, and has the advantages of being simple in model manufacturing operation, low in model manufacturing cost, short in model completing time, low in model dead rate, easy to duplicate, good in controllability, good in imaging effect and the like, beneficially for radioactivity lung injury experiment study and medical development and study such as relevant follow-up treatment, curative effect evaluation, and has scale popularization and application value.

The present invention provides an application of ITPP in preparing medicines for preventing and / or treating ischemia-hypoxic injury and lung injury, and relates to the technical field of biomedicine.In the provided examples, mice and rats are used as experimental materials and a mouse ischemia-hypoxic model and a rat lung injury model are established to explore preventive or therapeutic effects of the ITPP on the ischemia-hypoxia injury and lung injury. Tests prove that the ITPP can significantly prolong survival time of mice with ischemia and hypoxia induced by high-dose isoprenaline in a closed container; and the ITTP can significantly improve lung functions, lung coefficients, right lung wet and dry weight ratios, arterial oxygen content, serum inflammatory factors and lung tissue pathological changes of rats of the LPS-induced lung injury model, and has a significant improvement effect on lung injury tissues.

A system and method for measuring alveolar performance during ventilation using a microphone positioned adjacent to the distal end of a ventilation tube. The microphone is connected to a monitor that filters the signals received from the microphone to eliminate unwanted noise, such as that caused by the heart and turbulent airflow through the large airways of the lungs. The desired signals are then amplified and displayed on a graph as a function of lung volume during inflation. A clinician may take appropriate ventilation strategies based on the results displayed by the system to avoid ventilator induced lung injuries and decrease the mortality rates of patients having acute respiratory distress syndrome.

The invention relates to the technical field of medicines, and particularly discloses a pharmaceutical composition and application thereof in preparation of a medicine for treating acute lung injury. A composition for treating acute lung injury includes a compound and lidocaine. The pharmaceutical composition provided by the invention can reduce the death rate of animals with acute lung injury, wherein the compound and lidocaine are combined to play a synergistic role in reducing the lung coefficient, the lung permeability index, the release of inflammatory factors and the pathological score of lungs of the animals with acute lung injury.

The invention discloses an application of a pinus yunnanensis pine cone in preparing a medicament for treating acute lung injury. The invention also provides a preparation method of a pinus yunnanensis pine cone extract with a protection function on acute lung injury. Animal experiments prove that the pinus yunnanensis pine cone extract has the function of protecting acute lung injury, so that thepinus yunnanensis pine cone extract can be applied as health food. The main functional effects of the pinus yunnanensis pine cone extract are as follows: the pinus yunnanensis pine cone extract can lower relative mRNA expression of pro-inflammatory genes tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1beta) and interleukin 6 (IL-6) by inhibiting TLR4 / NF-kappa B signal pathway andoxidative stress in an acute lung injury (ALI) model, so that secretion of inflammatory factors is reduced, active oxygen free radicals are inhibited, activity of antioxidant enzymes is enhanced, andthus the pinus yunnanensis pine cone extract has a protective effect on LPS-induced rat ALI.

The present invention provides methods and compositions for treatment of acute inflammatory diseases or disorders and / or for treatment of lung injury. Certain exemplary methods involve administering an IL-4 polypeptide or fragment thereof possessing cytokine activity or an IL-4 agonist systemically to a subject having an inflammatory disease or disorder and / or a lung injury. Other exemplary methods involve administering an inhibitor of DNA methylation systemically to a subject and / or administering an inhibitor of DNA methylation to a cell population comprising T cells (e.g., Treg cells) for introduction / re-introduction to a subject having an inflammatory disease or disorder and / or a lung injury. Compositions and cells for use in such methods are also provided.